Gene theraphy for human lung cancer

Surgical Oncology Clinics of North America

Volumn 7, Issue 3, 1998, Pages 603-616

  Swisher, S G ^a   Roth, J A ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKINE; CYTOSINE DEAMINASE; DNA; GANCICLOVIR; PROTEIN P53; THYMIDINE KINASE;

ADENOVIRUS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; GENE THERAPY; GENE TRANSFER; HERPES SIMPLEX VIRUS; HUMAN; IMMUNOSTIMULATION; LUNG CANCER; LYMPHOKINE ACTIVATED KILLER CELL; ONCOGENE RAS; RETROVIRUS; REVIEW; SUICIDE GENE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR SUPPRESSOR GENE; LUNG TUMOR; MULTIMODALITY CANCER THERAPY;

CLINICAL TRIALS; COMBINED MODALITY THERAPY; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; LUNG NEOPLASMS;

EID: 0031596386     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1055-3207(18)30263-1     Document Type: Review

References (53)

1. Albelda S.M. Gene therapy for lung cancer and mesothelioma Chest 111 1997 144S 149S
2. Atkins M.B. Gould J.A. Allegretta M. Phase I evaluation of recombinant interleukin 2 in patients with advanced malignant disease J Clin Oncol 4 1986 1380 1391
3. Badie B. Drazan K.E. Kramar M.H. Adenovirus-mediated p53 gene delivery inhibits 9L glioma growth in rats Neurol Res 17 1995 209 216
4. Cai D.W. Mukhopadhyay T. Liu Y.J. Stable expression of the wild-type p53 gene in human lung cancer cells after retrovirus-mediated gene transfer Hum Gene Ther 4 1993 617 624
5. Calabretta B. Inhibition of protooncogene expression by antisense oligodeoxynucleotides: Biological and therapeutic implications Cancer Res 51 1991 4505 4510
6. Chang E.H. Miller P.S. Cushman C. Antisense inhibition of ras p21 expression that is sensitive to a point mutation Biochemistry 30:8283-8286 1991
7. Chang J.Y. Xia W.Y. Shao R.P. Inhibition of intratracheal lung cancer development by systemic delivery of E1A Oncogene 13 1996 1405 1412
8. Dubinett S.M. Kradin R.L. Cytokine immunotherapy of non-small cell lung cancer Reg Immunol 5 1993 232 243
9. Feng M. Cabrera G. Deshane J. Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme Cancer Res 55 1995 2024 2028
10. Fujiwara T. Cai D.W. Georges R.N. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model J Natl Cancer Inst 86 1994 1458 1462
11. Fujiwara T. Grimm E.A. Mukhopadhyay T. A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis Cancer Res 53 1993 4129 4133
12. Green D.R. McGahon A. Martin S.J. Regulation of apoptosis by oncogenes J Cell Biochem 60 1996 33 38
13. Grim J. Deshane J. Loechel F. Induction of apoptotic cell death in erbB-2 overexpressing tumor cells of diverse histologic subtypes mediated by intracellular localization of an anti-erbB-2 SFV [abstract] Cancer Gene Therapy 1 1994 333 334
14. Hallahan D.E. Mauceri H.J. Seung L.P. Spatial and temporal control of gene therapy using ionizing radiation Nature Medicine 1 1995 786 791
15. Heike Y. Takahashi M. Kanegae Y. Interleukin-2 gene transduction into freshly isolated lung adenocarcinoma cells with adenoviral vectors Hum Gene Ther 8 1997 1 14
16. Hwang H.C. Smythe W.R. Elshami A.A. Gene therapy using adenovirus carrying the herpes simplex-thymidine kinase gene to treat in vivo models of human malignant mesothelioma and lung cancer Am J Respir Cell Mol Biol 13 1995 7 16
17. mK4 gene mediated by an adenovirus vector Cancer Res 55 1995 3250 3253
18. Kashani-Sabet M. Funato T. Florenes V.A. Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme Cancer Res 54 1994 900 902
19. Kradin R.L. Kurnick J.T. Lazarus D.S. Tumor-infiltrating lymphocytes and interleukin-2 in the treatment of patients with advanced cancer Lancet 1 1989 577 580
20. Lee R.E. Lotze M.T. Skibber J.M. Cardiorespiratory effects of immunotherapy with interleukin-2 J Clin Oncol 7 1989 7 20
21. Liu T.J. Zhang W.W. Taylor D.L. Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus Cancer Res 54 1994 3662 3667
22. Mandelboim O. Vadai E. Feldman M. Expression of two H-2K genes, syngeneic and allogeneic, as a strategy for potentiating immune recognition of tumor cells Gene Therapy 2 1995 757 765
23. Marshall C.J. How does p21-ras transform cells? Trends Genet 7 1991 91 95
24. McBride W.H. Dougherty G.J. Radiotherapy for genes that cause cancer Nature Medicine 1 1995 1215 1217
25. Miller N. Whelan J. Progress in transcriptionally targeted and regulatable vectors for genetic therapy Hum Gene Ther 8 1997 803 815
26. Morita T. Ikeda K. Douzono M. Tumor vaccination with macrophage colony-stimulating factor-producing Lewis lung carcinoma in mice Blood 88 1996 955 961
27. Mukhopadhyay T. Maxwell S.A. Roth J.A. p53 Suppressor Gene 1995 RG Landes Austin
28. Mukhopadhyay T. Tainsky M. Cavender A.C. Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA Cancer Res 51 1991 1744 1748
29. Nguyen D.M. Spitz F.R. Yen N. Gene therapy for lung cancer: Enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirusmediated p53 gene transfer J Thorac Cardiovasc Surg 112 1996 1372 1377
30. Ohira T. Ohe Y. Heike Y. Gene therapy for Lewis lung carcinoma with tumor necrosis factor and interleukin 2 cDNAs co-transfected subline Gene Therapy 1 1994 269 275
31. Osaki T. Tanio Y. Tachibana I. Gene therapy for carcinoembryonic antigen-pro-ducing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene Cancer Res 54 1994 5258 5261
32. Richardson J.H. Marasco W.A. Intracellular antibodies: Development and therapeutic potential. Antibody engineering and single chain antibody gene transfer for intracellular immunization Trends in Biotechnology 13 1995 306 310
33. Rosenberg S.A. Lotze M.A. Muul L.M. A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin 2 or high dose interleukin 2 alone N Engl J Med 316 1987 889 897
34. Rosenberg S.A. Packard B.S. Aebersold P.M. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma N Engl J Med 319 1988 1676 1680
35. Roth J.A. Nguyen D. Lawrence D.D. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer Nature Medicine 2 1996 985 991
36. Sakakura C. Sweeney E.A. Shirahama T. Overexpression of bax sensitizes human breast cancer MCF-7 cells to radiationinduced apoptosis Int J Cancer 67 1996 101 105
37. Scanlon K. Jiao L. Funato T. Ribozyme-mediated cleavages of c-fos mRNA reduce gene expression of DNA synthesis enzymes and metallothionein Proc Natl Acad sci USA 88 1991 10591 10595
38. Schrump D.S. Chen A. Consoli U. Inhibition of lung cancer proliferation by antisense cyclin D Cancer Gene Therapy 3 1996 131 135
39. Smythe W.R. Hwang H.C. Elshami A.A. Differential sensitivity of thoracic malignant tumors to adenovirus-mediated drug sensitization gene therapy J Thorac Cardiovasc Surg 109 1995 626 631
40. Spitz F.R. Nguyen D. Skibber J.M. Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation Clinical Cancer Research 2 1996 1665 1671
41. Swisher S.G. Roth J.A. Lawrence D.D. Adenoviral mediated p53 gene transfer in patients with advanced non-small cell lung cancer (NSCLC) [abstract] Proceedings of the American Academy of Clinical Oncology 1565 1997 437a
42. Swisher SG, Roth JA, Lawrence DD, et al: Influence of serum antibodies to adenovirus on transgene persistence and expression following repeated injections of recombinant adenovirus containing wildtype p53 into tumors. Seminars in Oncology (submitted 1998)
43. Swisher S.G. Roth J.A. Lawrence D. Persistent transgene expression following repeated injections of a recombinant adenovirus containing the p53 wildtype gene in patients with non-small cell lung cancer [abstract] Proc Am Assoc Cancer Res 342 1997
44. Takahashi T. Carbone D. Nau M.M. Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions Cancer Res 52 1992 2340 2343
45. Tan Y.Y. Xu M.X. Wang W.G. IL-2 gene therapy of advanced lung cancer patients Anticancer Res 16 1996 1993 1998
46. Toloza E.M. Hunt K. Miller A.R. Transduction of murine and human tumors using recombinant adenovirus vectors Ann Surg Oncol 4 1997 70 79
47. Toloza E.M. Hunt K.K. Swisher S.G. In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector Cancer Gene Therapy 3 1996 11 17
48. Xu H.J. Zhou Y.L. Seigne J. Enhanced tumor suppressor gene therapy via replicationdeficient adenovirus vectors expressing an N-terminal truncated retinoblastoma protein Cancer Res 56 1996 2245 2249
49. Yung W.K.A. Shi Y.X. Zhang W.W. Growth suppression of human glioma cells by restoration of wild-type p53 gene utilizing an adenovirus vector [abstract] Proceedings of the American Association of Cancer Research 36 1995 423
50. Zhang W.W. Fang X. Mazur W. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus Cancer Gene Therapy 1 1994 5 13
51. Zhang Y.J. Mukhopadhyay T. Donehower L.W. Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype Hum Gene Ther 4 1993 451 460
52. Zhang Y. Yu D. Xia W. Her-2/neu- targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model Oncogene 10 1995 1947 1954
53. Zitvogel L. Tahara H. Robbins P.D. Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts J Immunol 155 1995 1393 1403